| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Clinical and Population Studies |
in Atherosclerosis and Plaque DestabilizationFrom the Research Institute for Internal Medicine (U.M.B., B.H., A.Y., C.S., K.O., T.W., W.J.S., S.S.F., J.K.D., P.A.), the Department of Pathology (J.H., G.H.), the Department of Cardiology (E.Ø., L.G.), the Institute for Surgical Research (E.Ø.), and the Section of Clinical Immunology and Infectious Diseases (S.S.F., J.K.D., P.A.), Rikshospitalet, University of Oslo, Norway; and the Department of Surgery (U.H.) and the Department of Medicine and Centre for Molecular Medicine (G.P.-B., G.K.H.), Karolinska University Hospital, Stockholm, Sweden.
Correspondence to Unni M. Breland, Research Institute for Internal Medicine, Rikshospitalet, N-0027 Oslo, Norway. E-mail Unni.Mathilde. Breland{at}rr-research.no
Abstract
Objective— We examined the role of the CXCR2 ligand growth-related oncogene (GRO)
in human atherosclerosis.
Methods and Results— GRO
levels were examined by enzyme immunoassay, real-time quantitative RT-PCR, and cDNA microarrays. The in vitro effect of statins on GRO
was examined in endothelial cells and THP-1 macrophages. Our main findings were: (1) GRO
was among the 10 most differentially expressed transcripts comparing peripheral blood mononuclear cells (PBMCs) from patients with coronary artery disease (CAD) and healthy controls. (2) Both patients with stable (n=41) and particularly those with unstable (n=47) angina had increased plasma levels of GRO
comparing controls (n=20). (3) We found increased expression of GRO
within symptomatic carotid plaques, located to macrophages and endothelial cells. (4) GRO
enhanced the release of matrix metalloproteinases in vascular smooth muscle cells, and increased the binding of acetylated LDL in macrophages. (5) Atorvastatin downregulated GRO
levels as shown both in vitro in endothelial cells and macrophages and in vivo in PBMCs from CAD patients. (6) The effect on GRO
in endothelial cells involved increased storage and reduced secretion of GRO
.
Conclusions— GRO
could be involved in atherogenesis and plaque destabilization, potentially contributing to inflammation, matrix degradation, and lipid accumulation within the atherosclerotic lesion.
The involvement of CXCR2 in atherogenesis is well recognized, thought to reflect interaction with interleukin-8. In the present study we found another CXCR2 ligand (ie, GRO
) to be significantly upregulated in human atherosclerosis both in circulating leukocytes and within the atherosclerotic lesion, potentially promoting matrix degradation, lipid accumulation, and inflammation.
Key Words: atherosclerosis chemokines inflammation endothelium
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |